Multiple sclerosis therapy enters phase 2

| Print |  Email
Articles - January 2013
Monday, December 10, 2012

 

BY LINDA BAKER

0113 GamePlan ArtielleMultiple sclerosis is an immune disorder in which the body mistakenly attacks the myelin sheath surrounding nerve fibers in the brain and spinal cord. The resulting neurological symptoms can range from numbness and tingling to paralysis. Although existing therapies reduce inflammation caused by MS, researchers have long sought to develop a therapy that will actually repair the neurological damage.

Enter Artielle ImmunoTherapeutics, a Portland biotech company that will launch an FDA phase-two clinical trial this year for a new therapy researchers say appears to also reverse the dysregulation of the immune system associated with MS and promotes nerve regeneration. The company takes its name from a phonetic rendering of its proprietary technology — recombinant T-cell receptor ligands.

“There is recovery from the disease,” says Arthur Vandenbark, a founding Artielle scientist and a neurology researcher affiliated with the Portland VA Medical Center and Oregon Health & Science University. “That’s what’s so exciting.” The phase-two trial is considered a critical milestone, as it will show the drug can work in MS patients — and not just in animal models. A phase-one trial, indicating the drug’s safety, was completed a few years ago. According to OHSU’s tech-transfer office, Artielle represents the first OHSU drug discovery to be commercialized this far in the clinical trial process by a company that was formed and has remained in Oregon.

Oregon can be a tough environment for homegrown biotech companies, which often struggle to locate investment capital. Founded eight years ago, Artielle is one of the success stories. It has raised $25 million of venture capital, including $2 million from Northwest Technology Ventures and Reference Capital Management, both located in Portland, and $11 million from Sanderling Ventures in the Bay Area, where Artielle CEO Peter McWilliams is based.

The phase-two trial is funded by the Department of Veterans Affairs and will help Artielle achieve its next financial goal: a buyout or partnership with a pharmaceutical company to help bring the product to market.

Only one in about 5,000 biotech startups develops a commercial drug, but the Artielle team thinks they have a shot. The market is saturated with purely anti-inflammatory drugs, says McWilliams. But Artielle’s technology goes further. “This is a disease-modifying agent,” he says.

 

Comments   

 
Guest
0 #1 new ms drugGuest 2013-01-09 19:02:09
what is the main component of the up coming new drug
Quote | Report to administrator
 
 
Guest
-1 #2 infoGuest 2013-02-09 20:49:44
This article gives some info:

http://www.msdiscovery.org/research-resources/drug-pipeline/499-rtl1000

Melanie J
Quote | Report to administrator
 

More Articles

Portland’s long-distance bike commuters

The Latest
Wednesday, July 29, 2015
Matt KellyresizethumbBY KIM MOORE | RESEARCH EDITOR

Pushing the extreme.


Read more...

The 5 highest revenue-generating parks in Oregon

The Latest
Thursday, June 11, 2015
parksthumbBY JACOB PALMER | DIGITAL NEWS EDITOR

In 2014, total revenue for camping and day use in Oregon State Parks was a little more than $17 million. That figure may even higher this year "because we've had exceptionally nice weather," Hughes says.


Read more...

Oregon needs a Grand Bargain energy plan

Linda Baker
Monday, June 22, 2015
0622-gastaxblogthumbBY LINDA BAKER

The Clean Fuels/gas tax trade off will go down in history as another disjointed, on-again off-again approach to city and state lawmaking.


Read more...

Storyteller in Chief: Natural Prophets

July/August 2015
Monday, July 13, 2015
BY SAM BLACKMAN

Storyteller-in-chief with the CEO and co-founder of Elemental Technologies.


Read more...

Preserving the Legacy

July/August 2015
Monday, July 13, 2015
BY KIM MOORE | PHOTOS BY JASON E. KAPLAN

A New York floral and gift business takes on the iconic Harry & David brand.


Read more...

5 things to know about veterans in the workforce

The Latest
Wednesday, July 01, 2015
070215-vetsthumbBY JACOB PALMER | DIGITAL NEWS EDITOR

There are more than 10 million former military members working in the United States.


Read more...

Balancing Act

July/August 2015
Friday, July 10, 2015
BY DAN COOK

The Affordable Care Act has triggered a rush on health care plan redesign, a process fraught with hidden costs and consequences.


Read more...
Oregon Business magazinetitle-sponsored-links-02
SPONSORED LINKS